GIPR and type 2 diabetes mellitus: 2022 FDA approval of dual agonists for GLP-1R and glucose-dependent insulinotropic polypeptide receptor (GIPR) tirzepatide to improve glycemic control in adults with T2DM as an adjunct to diet and exercise [123].